Lumiliximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lumiliximab ?
Monoclonal antibody
Type Whole antibody
Source Chimeric (primate/human)
Target CD23
Clinical data
Legal status
?
Identifiers
CAS number  YesY
ATC code None
UNII 8Z13S29R5A YesY
Chemical data
Formula C2115H3252N556O673S16 
Mol. mass 47.75 kDa
 N (what is this?)  (verify)

Lumiliximab is a monoclonal antibody that targets CD23. It acts as an immunomodulator[1] and, as of October 2009, it is being investigated in Phase I and II clinical trials for the treatment of chronic lymphocytic leukemia.[2][3] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]

References[edit]

  1. ^ a b International Nonproprietary Names for Pharmaceutical Substances (INN). World Health Organization.
  2. ^ Byrd, J. C.; Kipps, T. J.; Flinn, I. W.; Castro, J.; Lin, T. S.; Wierda, W.; Heerema, N.; Woodworth, J.; Hughes, S.; Tangri, S.; Harris, S.; Wynne, D.; Molina, A.; Leigh, B.; O'Brien, S. (2009). "Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia". Blood 115 (3): 489–495. doi:10.1182/blood-2009-08-237727. PMC 2810983. PMID 19843887.  edit
  3. ^ ClinicalTrials.gov NCT00801060